Release of our first CSR Report!
We’re excited to announce the publication of our first CSR Report!
Press releases
September 14, 2021
BMG Pharma and HTL sign a development agreement
The agreement between BMG Pharma and HTL will allow BMG Pharma to develop and commercialize injectable products with Sodium Hyaluronate Lipoate Formate (SHLF). BMG Pharma through its patented Hyaluromimethic® Technology works on SHLF to develop solutions in aesthetic dermatology, ophthalmology, and arthrosis.
– Thanks to this agreement, BMG Pharma will globally develop new formulations of its injectable products, always with high levels of quality, stability, and safety standards.
Read more below
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Press releases June 5, 2025HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
-
Press releases May 27, 2025HTL Biotechnology supports National Biomedicines manufacturing Day
HTL Biotechnology is proud to support National Biomedicines manufacturing Day, which will take place on June 5, 2025.
-
Articles April 2, 2025François Fournier Featured in Korean Press
HTL Biotechnology CEO François Fournier spoke to leading Korean media DongA Ilbo, reaffirming Korea’s strategic importance and the strong, long-standing ties with Korean customers.